TICKERNERD
Menu
ENSCENSCHealthcare · Biotechnology

ENSC Stock Forecast: Ensysce Biosciences, Inc. Price Predictions for 2026-2027

Last close, 13 Nov 2026
$0.41
+6.87% on the day

The 2 Wall Street analysts covering Ensysce Biosciences, Inc. hold a median 12-month price target of $2 — +383.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 13 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$8.0M
Ticker Nerd rank
34/ 100
Median analyst target
$2.00
Analysts covering
2
Revenue$0.0
Operating income−$2.6M
Net income−$2.6M
Free cash flow−$2.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+25.7%
1M
−27.8%
YTD
−55.0%
1Y
−80.0%
From 52W high
−80.0%
From 52W low
+64.8%
$0.25
$2.07
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ENSC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ensysce Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Nov 2026
34/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
92
Growth
74
Accruals
70
Revisions
60
Issuance
32
Momentum
29
Quality
7
Volatility
7
Value
5

Size (92): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ENSC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ENSC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26ENSCHigh $8.25Median $2.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $2.00Median $2.00High $8.25

The green dot is the last close — the median target sits +383.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Oct 2026Cantor FitzgeraldInitiatesOverweight$2.00
25 Sept 2023HC Wainwright & Co.MaintainsBuy$9.00 → $7.00
25 Sept 2023HC Wainwright & Co.MaintainsBuy—
3 July 2023HC Wainwright & Co.InitiatesBuy—
17 Nov 2022Lake StreetMaintainsBuy$80 → $8.00
30 Nov 2021Lake StreetInitiatesBuy$4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ENSC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ENSC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Nov 2026, Ensysce Biosciences, Inc. returned −80.0% against +13.4% for the S&P 500, dividends included.

ENSC vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26ENSCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ENSC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Ensysce Biosciences, Inc. (ENSC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
1.8×

Cheaper than 53% of US stocks

Price / book
−4.9×

Cheaper than 97% of US stocks

EV / EBITDA
−0.7×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
−15.1%

Higher than 14% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−281.3%

Higher than 9% of US stocks

Net margin
−280.5%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−1295.1%

Higher than 1% of US stocks

Return on assets
−185.5%

Higher than 1% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ensysce Biosciences, Inc. (ENSC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ensysce Biosciences, Inc. has a market value of $8.0M and an enterprise value of $6.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0. The latest quarter shrank 15.1% year on year.

  • Net income over the same four quarters: −$12.6M.

  • Diluted earnings per share, trailing twelve months: −$2.76.

  • Free cash flow in the twelve months to 30 June 2026: −$9.0M.

  • Shares outstanding: 15.4M.

  • Trailing P/E: 0.0×; forward P/E: −7.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Ensysce Biosciences, Inc. employs 8 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Nov 2026

Data provided by Twelve Data

Peers

ENSC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ENSCEnsysce Biosciences, Inc.$8.0M34
CALCCalciMedica, Inc.$8.3M37
MBRXMoleculin Biotech, Inc.$8.3M21
VTGNVistagen Therapeutics, Inc.$8.0M29
LGVNLongeveron, Inc.$7.9M48
MTVAMetaVia, Inc.$8.6M17
GTBPGT Biopharma, Inc.$7.7M14

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ensysce Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ENSC news & analysis

Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai

Accesswire · 21 Oct 2026positive

Ensysce Biosciences President James Morrison participated in the Family Office Summit in Dubai on October 15, 2026, as part of the company’s global investor and strategic outreach initiative. The announcement noted Ensysce’s work advancing CY200 and its severe pain pipeline.

Why it matters — The item gives ENSC watchers an update on the company’s investor outreach and development focus.

Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA

Accesswire · 24 Sept 2026positive

Ensysce Biosciences announced it submitted the protocol (CYBIO_001) for a Phase 2a clinical study of CY200 to the UK Medicines and Healthcare products Regulatory Agency (MHRA). The randomised, double-blind, placebo-controlled proof-of-concept study is designed to evaluate CY200's efficacy, safety, and tolerability in adults with Complex Regional Pain Syndrome Type 1.

Why it matters — This submission marks a key regulatory step toward initiating the first Phase 2 study of the newly acquired CY200 candidate, advancing Ensysce's CRPS-focused neuroplastogenic pipeline.

Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation

Accesswire · 15 Sept 2026positive

Ensysce Biosciences hosted a symposium at PainWeek 2026 attended by more than 320 pain management professionals, advancing its CRPS program. The company also contributed to an FDA hearing on psychedelic drug regulation.

Why it matters — The symposium attendance demonstrates growing engagement with pain management professionals for Ensysce's CRPS-focused neuroplastogenic pipeline, while its participation in the FDA hearing positions the company within broader regulatory discussions relevant to its therapy area.

Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

Accesswire · 14 Sept 2026positive

Ensysce Biosciences announced that Richard Langford, Chief Medical Officer of Cy Biopharma, has been selected to present in person at an FDA public hearing on potential future therapeutic use of psychedelic drugs, taking place September 14, 2026 at the FDA's White Oak Campus in Maryland. Dr. Langford is among a limited group of stakeholders invited to provide comments during the afternoon session on considerations for access and best practices for data collection and standardization.

Why it matters — The selection of Dr. Langford to speak at a major FDA hearing highlights Ensysce's engagement with regulators and its visibility as a clinical-stage biotech developing novel neuroplastogenic therapies.

Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation

Accesswire · 2 Sept 2026neutral

Ensysce Biosciences announced its participation in upcoming investor conferences and industry events, including the 2026 Cantor Global Healthcare Conference to be held September 9-12 at the Waldorf Astoria in New York City. The clinical-stage biotech company is developing novel neuroplastogenic therapies with an initial focus on CRPS.

Why it matters — ENSC watchers would care because the company's participation in these conferences may provide opportunities for investor exposure and updates on its clinical-stage pipeline focused on CRPS.

FAQ

Frequently asked questions about ENSC stock

What is the ENSC stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Ensysce Biosciences, Inc. have a median 12-month price target of $2, with estimates ranging from $2 to $8.25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ENSC stock a buy right now?

Of the 2 analysts covering Ensysce Biosciences, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ensysce Biosciences, Inc. 34 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ENSC?

As at 13 Nov 2026, Ensysce Biosciences, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).

Will ENSC stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +383.6% from the last close, and Ticker Nerd's factor model ranks Ensysce Biosciences, Inc. 34 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ENSC stock forecast for 2030?

No analyst covering Ensysce Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENSC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $8.25 over the next 12 months.

How has ENSC stock performed over the past year?

Ensysce Biosciences, Inc. returned -80.0% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ensysce Biosciences, Inc. do?

Ensysce Biosciences, Inc. Common Stock represents ownership in Ensysce Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing prescription therapies for severe pain and central nervous system conditions.

What is the latest news on ENSC?

The most recent item we track (Accesswire, 21 Oct 2026): "Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai". Ensysce Biosciences President James Morrison participated in the Family Office Summit in Dubai on October 15, 2026, as part of the company’s global investor and strategic outreach initiative. The announcement noted Ensysce’s work advancing CY200 and its severe pain pipeline.

Company

About Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. Common Stock represents ownership in Ensysce Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing prescription therapies for severe pain and central nervous system conditions. The company’s current work centers on proprietary drug-delivery and abuse-deterrence platforms, including Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), which are designed to improve how certain medications are activated and to reduce the risks of misuse, abuse, and overdose. Its pipeline includes candidates for pain management, opioid protection, and attention deficit hyperactivity disorder, reflecting a focus on controlled pharmaceutical innovation rather than broad commercial medicines. Based in La Jolla, California, Ensysce Biosciences operates in the biotechnology and pharmaceuticals segment of the healthcare market, where it contributes to research-driven solutions aimed at safer treatment options for patients and clinicians.

CEO Dr. D. Lynn Kirkpatrick Ph.D. · 8 employees · United States · https://www.ensysce.com